Tag Archives: Momelotinib: US approves GSK’s bone marrow cancer therapy

British drugmaker GSK said on Friday the U.S. Food and Drug Administration had approved its oral therapy to treat anemia in patients with a type of bone marrow cancer called myelofibrosis. The approval comes after the health regulator in July delayed its decision to review additional data. The therapy, momelotinib, has been approved for patients “regardless of prior myelofibrosis therapy”, …

Read More »